Cybin Inc. (NYSE:CYBN) has completed dosing of the final participant cohort in the Phase 2 study on its deuterated psilocybin analog CYB003 for Major Depressive Disorder (MDD) treatment. The company expects to provide topline efficacy data before the end of the year. Cybin will now focus on the upcoming data submission to the FDA toward a potential scaling to a Phase 3 pivotal study in early 2024. The Phase 1/2 study evaluated CYB003’s safety, tolerability, PK/PD and psychedelic effect in ascending oral doses in both participants with MDD and healthy volunteers.